Holen Sie sich die Stockscreener-App
3.84
4.07%
0.15
Handel nachbörslich:
3.81
-0.03
-0.78%
Schlusskurs vom Vortag:
$3.69
Offen:
$3.71
24-Stunden-Volumen:
515.99K
Relative Volume:
0.87
Marktkapitalisierung:
$314.74M
Einnahmen:
$153.73M
Nettoeinkommen (Verlust:
$-106.79M
KGV:
-1.5547
EPS:
-2.47
Netto-Cashflow:
$-115.93M
1W Leistung:
+8.17%
1M Leistung:
+6.37%
6M Leistung:
+0.26%
1J Leistung:
+34.74%
1-Tages-Spanne:
$3.595
$3.86
1-Wochen-Bereich:
$3.22
$3.86
52-Wochen-Spanne:
$2.005
$6.13
Sutro Biopharma Inc Stock (STRO) Company Profile
Firmenname
Sutro Biopharma Inc
Sektor
Branche
Telefon
650-392-8412
Adresse
111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Sutro Biopharma Inc Stock (STRO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-03-21 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-08-18 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-06-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-12-03 | Eingeleitet | Stifel | Buy |
| 2020-09-02 | Eingeleitet | Jefferies | Buy |
| 2020-07-16 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-13 | Eingeleitet | SunTrust | Buy |
| 2019-10-07 | Eingeleitet | BTIG Research | Buy |
| 2019-07-18 | Eingeleitet | Deutsche Bank | Buy |
| 2019-04-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-10-22 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2018-10-22 | Eingeleitet | Piper Jaffray | Overweight |
| 2018-10-22 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Sutro Biopharma Inc Aktie (STRO) Neueste Nachrichten
Vanguard Group Inc's Strategic Acquisition in Sutro Biopharma Inc - GuruFocus.com
Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference - The Manila Times
Sutro Biopharma begins trial of acute myeloid leukaemia treatment in children - Clinical Trials Arena
Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Rating of “Buy” from Brokerages - Defense World
Sutro Biopharma, Inc. (NASDAQ:STRO) Receives $12.13 Average PT from Brokerages - MarketBeat
Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML - The Manila Times
Sutro Biopharma's SWOT analysis: stock poised for growth amid clinical progress - Investing.com
The Manufacturers Life Insurance Company Buys 7,082 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Sutro Biopharma (NASDAQ:STRO) shareholders have endured a 80% loss from investing in the stock three years ago - Yahoo Finance
Sutro Biopharma, Inc. (NASDAQ:STRO) Shares Sold by Cubist Systematic Strategies LLC - MarketBeat
Sutro Biopharma: Post ESMO Selloff, Does Their Strategy In FRα Remain Viable? - Seeking Alpha
Sutro Biopharma Inc Inc. (STRO) Price Performance: A Comparative Analysis with Competitors - The InvestChronicle
Algert Global LLC Reduces Stake in Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
AQR Capital Management LLC Boosts Stock Position in Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
AQR Capital Management LLC Buys 247,694 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) - MarketBeat
HC Wainwright Reiterates “Buy” Rating for Sutro Biopharma (NASDAQ:STRO) - Defense World
Sutro Biopharma (NASDAQ:STRO) & Palisade Bio (NASDAQ:PALI) Head-To-Head Contrast - Defense World
Piper Sandler sustains Overweight rating on Sutro Biopharma shares By Investing.com - Investing.com Canada
Sutro Biopharma retains stock target with Buy rating on key advancements - Investing.com Canada
Peeling Back The Layers: Exploring Sutro Biopharma Through Analyst Insights - Benzinga
Sutro Biopharma (NASDAQ:STRO) Stock Rating Reaffirmed by HC Wainwright - MarketBeat
Revenues Working Against Sutro Biopharma, Inc.'s (NASDAQ:STRO) Share Price Following 25% Dive - Simply Wall St
Sutro Biopharma, Inc. (NASDAQ:STRO) Shares Sold by Dimensional Fund Advisors LP - MarketBeat
After-Market Gains For Sutro Biopharma (STRO) Following An Investor Webcast - Stocks Telegraph
Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum - GlobeNewswire
Sutro Biopharma, Inc. (NASDAQ:STRO) Receives $12.13 Average Price Target from Analysts - MarketBeat
Sutro Biopharma, Inc. (NASDAQ:STRO) Shares Bought by ProShare Advisors LLC - Defense World
Cubist Systematic Strategies LLC Trims Stock Position in Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Millennium Management LLC Has $12.78 Million Holdings in Sutro Biopharma, Inc. (NASDAQ:STRO) - MarketBeat
It would be worthwhile to take a closer look at Sutro Biopharma Inc (STRO) - US Post News
Financial Metrics Unveiled: Sutro Biopharma Inc (STRO)’s Key Ratios in the Spotlight - The Dwinnex
American Century Companies Inc. Trims Stock Position in Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Susquehanna Fundamental Investments LLC Grows Stake in Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Renaissance Technologies LLC Buys 233,700 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) - MarketBeat
A better buy-in window may exist right now for Sutro Biopharma Inc (STRO) - SETE News
XTX Topco Ltd Has $95,000 Stock Holdings in Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Point72 Asset Management L.P. Increases Holdings in Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Investing in Sutro Biopharma Inc (STRO) might be an excellent idea, but the stock is currently overvalued/undervalued - US Post News
Sutro Biopharma's SWOT analysis: ADC developer's stock faces pivotal year By Investing.com - Investing.com Canada
Sutro Biopharma's SWOT analysis: ADC developer's stock faces pivotal year - Investing.com India
STRO (Sutro Biopharma) Enterprise Value : $-114.2 Mil (As of Sep. 28, 2024) - GuruFocus.com
Check out these key findings about Sutro Biopharma Inc (STRO) - SETE News
STRO’s 2023 Market Dance: Down -20.75% – Time to Invest? - The InvestChronicle
Sutro Biopharma Inc (STRO) presents a great opportunity, but the stock is slightly undervalued - US Post News
Sutro Biopharma's Competitive ADCs Position It For Future Growth In Oncology - Seeking Alpha
Sutro Biopharma Inc’s Market Journey: Closing Weak at 3.77, Down -3.83 - The Dwinnex
Bank of New York Mellon Corp Increases Position in Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - ForexTV.com
Institutional investors may overlook Sutro Biopharma, Inc.'s (NASDAQ:STRO) recent US$43m market cap drop as long-term gains remain positive - Simply Wall St
Cancer Research Sees Major Boost as New Breakthroughs Emerge from Key Oncology Players - Benzinga
Ready to Jump After Recent Trade: Sutro Biopharma Inc (STRO) - SETE News
Finanzdaten der Sutro Biopharma Inc-Aktie (STRO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Sutro Biopharma Inc-Aktie (STRO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Chung Jane | PRESIDENT AND COO |
Aug 09 '24 |
Option Exercise |
0.00 |
18,750 |
0 |
60,951 |
| Srinivasan Venkatesh | CHIEF TECH OP OFFICER |
May 01 '24 |
Option Exercise |
0.00 |
2,500 |
0 |
32,622 |
| Srinivasan Venkatesh | CHIEF TECH OP OFFICER |
Apr 11 '24 |
Option Exercise |
0.00 |
21,250 |
0 |
37,704 |
| FITZPATRICK LINDA A | CHIEF PEOPLE & COMM. OFFICER |
Mar 05 '24 |
Option Exercise |
0.00 |
8,750 |
0 |
76,060 |
| NEWELL WILLIAM J | CEO |
Mar 05 '24 |
Option Exercise |
0.00 |
18,750 |
0 |
226,893 |
| ALBINI EDWARD C | CFO AND SECRETARY |
Mar 05 '24 |
Option Exercise |
0.00 |
8,750 |
0 |
109,843 |
| NEWELL WILLIAM J | CEO |
Mar 04 '24 |
Option Exercise |
0.00 |
31,125 |
0 |
219,248 |
| FITZPATRICK LINDA A | CHIEF PEOPLE & COMM. OFFICER |
Mar 04 '24 |
Option Exercise |
0.00 |
9,125 |
0 |
71,049 |
| Chung Jane | PRESIDENT AND COO |
Mar 04 '24 |
Option Exercise |
0.00 |
7,875 |
0 |
44,410 |
| ALBINI EDWARD C | CFO AND SECRETARY |
Mar 04 '24 |
Option Exercise |
0.00 |
9,125 |
0 |
104,565 |
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):